Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma

Journal of Immunology

Volumn 175, Issue 9, 2005, Pages 6169-6176

  Rosenberg, Steven A ^a   Sherry, Richard M ^a   Morton, Kathleen E ^a   Scharfman, William J ^a,b   Yang, James C ^a   Topalian, Suzanne L ^a   Royal, Richard E ^a   Kammula, Udai ^a   Restifo, Nicholas P ^a   Hughes, Marybeth S ^a   Schwartzentruber, Douglas ^a   Berman, David M ^a   Schwarz, Susan L ^a   Ngo, Lien T ^a   Mavroukakis, Sharon A ^a   White, Donald E ^a   Steinberg, Seth M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GLYCOPROTEIN GP 100; HLA A ANTIGEN; SYNTHETIC PEPTIDE; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER PATIENT; CARCINOGENESIS; CYTOKINE RELEASE; DISEASE COURSE; GENE IDENTIFICATION; GENE MUTATION; GROWTH INHIBITION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 27144500671     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.9.6169     Document Type: Article

References (36)

1. Sherman, L. A., M. Theobald, D. Morgan, J. Hernandez, I. Bacik, J. Yewdell, J. Bennink, and J. Biggs. 1998. Strategies for tumor elimination by cytotoxic T lymphocytes. Crit. Rev. Immunol. 18: 47-54.
2. Ostrand-Rosenberg, S. 2004. Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr. Opin. Immunol. 16: 143-150.
3. Lyerly, H. K. 2003. Quantitating cellular immune responses to cancer vaccines. Semin. Oncol. 30: 9-16.
4. Valmori, D., and M. Ayyoub. 2004. Using modified antigenic sequences to develop cancer vaccines: are we losing the focus? Plos. Med. 1: e26.
5. Celis, E. 2002. Getting peptide vaccines to work: just a matter of quality control? J. Clin. Invest. 110: 1765-1768.
6. Mahnke, Y. D., D. Speiser, I. F. Luescher, J. C. Cerottini, and P. Romero. 2005. Recent advances in tumour antigen-specific therapy: in vivo veritas. Int. J. Cancer 113: 173-178.
7. Rosenberg, S. A., J. C. Yang, and N. P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10: 909-915.
8. Marshall, J. L., R. J. Hoyer, M. A. Toomey, K. Faraguna, P. Chang, E. Richmond, J. E. Pedicano, E. Gehan, R. A. Peck, P. Arlen, et al. 2000. Phase 1 study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J. Clin. Oncol. 18: 3964-3973.
9. Eder, J. P., P. W. Kantoff, K. Roper, G. X. Xu, G. J. Bubley, J. Boyden, L. Gritz, G. Mazzara, W. K. Oh, P. Arlen, et al. 2000. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res. 6: 1632-1638.
10. Gulley, J., A. P. Chen, W. Dahut, P. M. Arlen, A. Bastian, S. M. Steinberg, K. Tsang, D. Panicali, D. Poole, J. Schlom, and H. J. Michael. 2002. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 53: 109-117.
11. Slingluff, C. L., Jr., G. Yamshchikov, P. Neese, H. Galavotti, S. Eastham, V. H. Engelhard, D. Kittlesen, D. Deacon, S. Hibbitts, W. W. Grosh, et al. 2001. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin. Cancer Res. 7: 3012-3024.
12. + melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin. Cancer Res. 8: 967-972.
13. Clay, T. M., A. C. Hobeika, P. J. Mosca, H. K. Lyerly, and M. A. Morse. 2001. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin. Cancer Res. 7: 1127-1135.
14. Walker, E. B., and M. L. Disis. 2003. Monitoring immune responses in cancer patients receiving tumor vaccines. Int. Rev. Immunol. 22: 283-319.
15. Dyall, R., W. B. Bowne, L. W. Weber, J. LeMaoult, P. Szabo, Y. Moroi, G. Piskun, J. J. Lewis, A. N. Houghton, and J. Nikolic-Zugic. 1998. Heteroclitic immunization induces tumor immunity. J. Exp. Med. 188: 1553-1561.
16. Parkhurst, M. R., M. L. Salgaller, S. Southwood, P. F. Robbins, A. Sette, S. A. Rosenberg, and Y. Kawakami. 1996. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157: 2539-2548.
17. Yu, Z., M. R. Theoret, C. E. Touloukian, D. R. Surman, S. C. Carman, L. Feigenbaum, T. K. Baxter, B. M. Baker, and N. P. Restifo. 2004. Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. J. Clin. Invest 114: 551-559.
18. Borbulevych, O. Y., T. K. Baxter, Z. Yu, N. P. Restifo, and B. M. Baker. 2005. Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design. J. Immunol. 174: 4812-4820.
19. Matsui, M., R. J. Moots, R. J. Warburton, A. L. Peace-Brewer, L. G. Tussey, D. G. Quinn, A. J. McMichael, and J. A. Frelinger. 1995. Genetic evidence for difference between intracellular and extracellular peptides in influenza A matrix peptide-specific CTL recognition. J. Immunol. 154: 1088-1096.
20. Pass, H. A., S. L. Schwarz, J. R. Wunderlich, and S. A. Rosenberg. 1998. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J. Sci. Am. 4: 316-323.
21. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4: 321-327.
22. Germeau, C., W. Ma, F. Schiavetti, C. Lurquin, E. Henry, N. Vigneron, F. Brasseur, B. Lethe, E. De Plaen, T. Velu, et al. 2005. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J. Exp. Med. 201: 241-248.
23. Scheibenbogen, C., A. Schmittel, U. Keilholz, T. Allgauer, U. Hofmann, R. Max, E. Thiel, and D. Schadendorf. 2000. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J. Immunother. 23: 275-281.
24. Coulie, P. G., V. Karanikas, D. Colau, C. Lurquin, C. Landry, M. Marchand, T. Dorval, V. Brichard, and T. Boon. 2001. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc. Natl. Acad. Sci. USA 98: 10290-10295.
25. + T lymphocytes in patients undergoing multiple course peptide vaccination. J. Immunother. 27: 36-47.
26. Khong, H. T., and N. P. Restifo. 2002. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 3: 999-1005.
27. Talebi, T., and J. S. Weber. 2003. Peptide vaccine trials for melanoma: preclinical background and clinical results. Semin. Cancer Biol. 13: 431-438.
28. Romero, P., J. C. Cerottini, and D. E. Speiser. 2004. Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. Cancer Immunol. Immunother. 53: 249-255.
29. Wang, F., E. Bade, C. Kuniyoshi, L. Spears, G. Jeffery, V. Marty, S. Groshen, and J. Weber. 1999. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin. Cancer Res. 5: 2756-2765.
30. + T-cell responses. J. Clin. Oncol. 21: 1562-1573.
31. Lee, P., F. Wang, J. Kuniyoshi, V. Rubio, T. Stuges, S. Groshen, C. Gee, R. Lau, G. Jeffery, K. Margolin, et al. 2001. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J. Clin. Oncol. 19: 3836-3847.
32. Takeda, K., T. Kaisho, and S. Akira. 2003. Toll-like receptors. Annu. Rev. Immunol. 21: 335-376.
33. Waldmann, T. A., S. Dubois, and Y. Tagaya. 2001. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 14: 105-110.
34. Phan, G. Q., J. C. Yang, R. M. Sherry, P. Hwu, S. L. Topalian, D. J. Schwartzentruber, N. P. Restifo, L. R. Haworth, C. A. Seipp, L. J. Freezer, et al. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100: 8372-8377,
35. Dudley, M. E., J. R. Wunderlich, J. C. Yang, R. M. Sherry, S. L. Topalian, N. P. Restifo, R. E. Royal, U. Kammula, D. E. White, S. A. Mavroukakis, et al. 2005. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23: 2346-2357.
36. + T cells. J. Exp. Med. 198: 569-580.